| General Information | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000013975397 |
| Molecular Weight (Da) | 398 |
| SMILES | COc1cccc2c(C(=O)N3C[C@H](C)N(C)[C@H](C)C3)cn(CC3CCCCC3)c12 |
| Molecular Formula | C24N3O2 |
| Action | Agonist |
| General Information | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000013975397 |
| Molecular Weight (Da) | 398 |
| SMILES | COc1cccc2c(C(=O)N3C[C@H](C)N(C)[C@H](C)C3)cn(CC3CCCCC3)c12 |
| Molecular Formula | C24N3O2 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000013975397 |
| Molar Refractivity | 115.391 |
| HBA | 2 |
| HBD | 0 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 29 |
| LogP | 4.401 |
| Activity (Ki) in nM | 0.794 |
| Polar Surface Area (PSA) | 37.71 |
| Pharmacokinetic Properties | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000013975397 |
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Oatp2b1 inhibitor | - |
| Oatp1b1 inhibitor | + |
| Oatp1b3 inhibitor | + |
| Mate1 inhibitor | - |
| Oct2 inhibitor | + |
| Bsep inhibitor | + |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | - |
| Androgen receptor binding | + |
| Plasma protein binding | 0.814 |
| Pharmacokinetic Properties | |
|---|---|
| Number of aromatic heavy atoms | 9 |
| Fraction csp3 | 0.62 |
| Ilogp | 4.25 |
| Xlogp3 | 4.41 |
| Wlogp | 3.63 |
| Mlogp | 2.98 |
| Silicos-it log p | 3.19 |
| Consensus log p | 3.69 |
| Esol log s | -4.98 |
| Esol solubility (mg/ml) | 0.00414 |
| Esol solubility (mol/l) | 0.0000104 |
| Esol class | Moderately |
| Ali log s | -4.92 |
| Ali solubility (mg/ml) | 0.00479 |
| Ali solubility (mol/l) | 0.000012 |
| Ali class | Moderately |
| Silicos-it logsw | -4.78 |
| Silicos-it solubility (mg/ml) | 0.00657 |
| Silicos-it solubility (mol/l) | 0.0000165 |
| Silicos-it class | Moderately soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.59 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 0 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.93 |
| Pharmacokinetic Properties | |
|---|---|
| Logs | -5.238 |
| Logd | 3.684 |
| Logp | 4.343 |
| F (20%) | 0.027 |
| F (30%) | 0.004 |
| Mdck | 1.64E-05 |
| Ppb | 0.8509 |
| Vdss | 0.826 |
| Fu | 0.0528 |
| Cyp1a2-inh | 0.276 |
| Cyp1a2-sub | 0.937 |
| Cyp2c19-inh | 0.804 |
| Cyp2c19-sub | 0.938 |
| Cl | 4.113 |
| T12 | 0.036 |
| H-ht | 0.967 |
| Dili | 0.842 |
| Roa | 0.059 |
| Fdamdd | 0.928 |
| Skinsen | 0.143 |
| Ec | 0.003 |
| Ei | 0.013 |
| Respiratory | 0.882 |
| Bcf | 1.698 |
| Igc50 | 4.629 |
| Lc50 | 5.448 |
| Lc50dm | 5.309 |
| Nr-ar | 0.003 |
| Nr-ar-lbd | 0.001 |
| Nr-ahr | 0.012 |
| Nr-aromatase | 0.003 |
| Nr-er | 0.421 |
| Nr-er-lbd | 0.031 |
| Nr-ppar-gamma | 0.011 |
| Sr-are | 0.34 |
| Sr-atad5 | 0.002 |
| Sr-hse | 0.007 |
| Sr-mmp | 0.032 |
| Sr-p53 | 0.006 |
| Vol | 426.823 |
| Dense | 0.931 |
| Flex | 0.217 |
| Nstereo | 2 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 0 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | 0 |
| Toxicophores | 2 |
| Qed | 0.768 |
| Synth | 3.295 |
| Fsp3 | 0.625 |
| Mce-18 | 80.795 |
| Natural product-likeness | -0.678 |
| Alarm nmr | 1 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 0 |
| Gsk | Rejected |
| Goldentriangle | Accepted |